ClinicalTrials.gg
Active, not recruitingNCT04739813Updated Nov 12, 2026Results posted

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

A Phase 1 interventional study of Obinutuzumab and Prednisone in Lymphoma, Non-Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma, sponsored by National Cancer Institute (NCI). Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Primary conditionLymphoma, Non-HodgkinRegistry: LymphomaReclassifiedWhy we changed it
Registry
Lymphoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Non-Hodgkin
Why
  1. The study's listed conditions name Lymphoma, Non-Hodgkin, a narrower term within Lymphoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Cancer Institute (NCI) · Phase 1, Interventional, and Treatment

How we know

Updated Nov 12, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Non-randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 136 studies in Lymphoma, Non-Hodgkin by National Cancer Institute (NCI) — 10 open to participants now, 22 under way, none of them phase 3. Lymphoma, Non-Hodgkin · National Cancer Institute (NCI).

Enrollment
38th of 113
49 · median 35
Started
2021
with 1 other
Phase 1
67 of 136
1 open now
Primary completion
2026-05
later than 9 of 17 live
Registered
131st of 136
by date

Among the 136 studies in Lymphoma, Non-Hodgkin by National Cancer Institute (NCI), this one is the 38th largest by enrollment of the 113 interventional ones that give a count, is one of 2 that started in 2021, is one of 67 in phase 1, reaches primary completion later than 9 of the 17 other live ones, and was the 131st registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

10 of the 136 studies in Lymphoma, Non-Hodgkin by National Cancer Institute (NCI) are open now, in 2 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Lymphoma, Non-Hodgkin by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

Background:

Aggressive B-cell lymphomas can be cured but people with disease that resists treatment or that returns after treatment have poor outcomes with standard therapies. Indolent B-cell lymphomas are generally incurable with standard therapy and treatment is aimed at controlling symptoms and achieving a durable remission. Researchers want to see if a combination of drugs can help patients with both aggressive and indolent B-cell lymphomas.

Objective:

To learn if it is safe and effective to give polatuzumab along with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide to people with certain B-cell lymphomas.

Eligibility:

Adults ages 18 and older with relapsed and/or refractory B-cell lymphoma who have had at least one prior cancer treatment.

Design:

Participants will be screened with:

Medical history

Physical exam

Assessment of how they do their daily activities

Blood and urine tests

Heart function test

Tissue biopsy (if needed)

Body imaging scans (may get a contrast agent through an intravenous (IV) catheter)

Participants will have a bone marrow aspiration and/or biopsy. A needle will be put into the hipbone. Bone marrow will be removed.

Participants may give blood, tissue, saliva, or cheek swab samples. They may have optional biopsies.

Screening tests will be repeated during the study.

Treatment will be given for up to 6 cycles. Each cycle lasts 21 days.

Participants will take venetoclax and prednisone tablets by mouth. They will take ibrutinib and lenalidomide capsules by mouth. They will get obinutuzumab and polatuzumab by IV infusion. They will keep a medicine diary.

Participants will visit the clinic 30 days after treatment ends. They will have follow-up visits for 5 years. If needed, they can visit their local doctor instead. They may be contacted by phone, mail, etc., for the rest of their life....

Read the detailed description

Background:

  • Combination chemotherapy with rituximab has been the mainstay of treatment for cluster of differentiation 20 (CD20)-positive B-cell lymphomas.
  • Significant advances have been made in curing aggressive B-cell lymphomas with chemoimmunotherapy, but indolent lymphomas and relapsed/refractory aggressive lymphomas remain mostly incurable with chemotherapy alone.
  • Targeted therapies, aimed at disrupting key survival pathways in lymphoid malignancies, are emerging and showing significant activity in non-Hodgkin lymphoma (NHL) in both the relapsed and first-line settings.
  • Mechanistically based combinations of targeted agents are likely to benefit patients who cannot tolerate or who relapse after or are refractory to standard chemoimmunotherapy.
  • Venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide (or Revlimid), plus polatuzumab vedotin (ViPOR-P) targets major survival pathways in B-cell lymphomas including B-cell lymphoma 2 (BCL-2 (apoptosis); Bruton's tyrosine kinase (BTK (B-cell receptor signaling and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB); Cereblon (NF-kB) and CD20 with additional genotoxic stress from the anti-mitotic antibody-drug conjugate targeting cluster of differentiation 79b (CD79b), polatuzumab.

Objectives:

  • To determine the maximum tolerated dose (MTD) and the safety and toxicity profile of polatuzumab and venetoclax in combination with ibrutinib, prednisone, obinutuzumab and Revlimid (lenalidomide) (ViPOR-P) in relapsed/refractory B-cell lymphomas
  • To determine the complete response (CR) rate of ViPOR-P in relapsed/refractory non-germinal center B-cell-like (non-GCB)

Diffuse large B-cell lymphoma (DLBCL)

Eligibility:

  • Individuals >= 18 years of age
  • Eastern Cooperative Oncology Group (ECOG) performance status of \<= 2
  • Histologically or cytologically confirmed relapsed and/or refractory B-cell lymphoma, excluding mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
  • Adequate organ function unless dysfunction secondary to lymphoma

Design:

  • Open-label, single-center, non-randomized phase 1 study
  • Standard 3 + 3 design will be used to determine the MTD of polatuzumab and venetoclax in combination with ibrutinib, prednisone, obinutuzumab and Revlimid (lenalidomide) (ViPOR-P) in relapsed/refractory B-cell lymphomas
  • A small expansion cohort will be treated at the MTD for a further analysis of safety and preliminary activity.
  • An expansion cohort of 32 patients (including 27 new patients + 5 patients already enrolled at dose level 3 (DL3)/MTD) with non-GCB DLBCL will be treated at the MTD to determine the CR rate to ViPOR-P of this aggressive lymphoma subtype.
  • Maximum 6 cycles of combination targeted therapy every 21 days.
  • To explore all dose levels in the phase 1 study and to assess the CR rate in non-GCB

DLBCL patients in a dose expansion at the MTD as well as to allow for the possibility of a few screen failures and inevaluable subjects, the accrual ceiling will be set at 55 patients.

03

Conditions studied

  • Lymphoma
  • Non-Hodgkin Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Burkitt Lymphoma

Keywords

  • Monoclonal Antibody
  • Dose Finding
04

In context

Lymphoma, Non-Hodgkin Reclassified

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

This study's enrollment of 49 is above the median of 40 across 1,884 interventional studies indexed under Lymphoma, Non-Hodgkin.

Browse Lymphoma, Non-Hodgkin studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.

Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.

Compared within Lymphoma, Non-Hodgkin, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have or cytologically confirmed B-cell lymphoma confirmed by the Laboratory of Pathology, National Cancer Institute (NCI), as follows:

Cohorts 1 and 2:

  • Aggressive B-cell lymphoma: includes diffuse large B-cell lymphoma (DLBCL) and subtypes, transformed lymphoma, Burkitt lymphoma, as well as high-grade B-cell lymphoma with MYC and/or B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangement(s).
  • Indolent B-cell lymphoma: with the following exceptions:

    • Mantle cell lymphoma (MCL) is excluded given increased risk of tumor lysis syndrome (TLS) with venetoclax compared to other non-Hodgkin lymphomas and need for venetoclax ramp-up, dose-escalation.
    • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) is excluded given alternative dosing of Food and Drug Administration (FDA)-approved venetoclax for CLL/SLL and increased risk of TLS with CLL/SLL compared to other non-Hodgkin lymphomas.

Cohort 3:

-Non-germinal center B-cell-like (Non-GCB) DLBCL: includes DLBCL not otherwise specified (NOS) and subtypes, transformed lymphoma, T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL), as well as high-grade B-cell lymphoma with MYC and/or BCL6 rearrangement(s).

NOTE: Patients with known active central nervous system (CNS) lymphoma are not eligible.

  • Relapsed and/or refractory disease after at least 1 prior treatment regimen, as follows:

    • Aggressive B-cell lymphoma: relapsed after and/or refractory to at least 1 prior anthracycline-containing regimen
    • Indolent B-cell lymphoma: relapsed after and/or refractory to at least 1 prior anti-cluster of differentiation 20 (CD20) antibody-containing regimen.
  • Patients must have evaluable disease by clinical exam (i.e., palpable lymphadenopathy, measurable skin lesions, etc.), laboratory assessment (i.e., lymphoma involvement of bone marrow or peripheral blood by morphology, cytology or flow cytometry), and/or imaging (measurable lymph nodes or masses on computed tomography (CT) or magnetic resonance imaging (MRI) and/or evaluable fluorodeoxyglucose (FDG)-avid lesions on positron emission tomography (PET).

NOTE: Lesions that have been irradiated cannot be included in the tumor assessment unless unequivocal tumor progression has been documented in these lesions after radiation therapy.

-Age >=18 years

NOTE: Because no dosing or adverse event data are currently available on the use of polatuzumab in combination with venetoclax, ibrutinib, obinutuzumab, prednisone and Revlimid(R) in patients \<18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.

  • Eastern Cooperative Oncology () performance status \<=2.
  • Adequate organ and marrow function as defined below unless dysfunction is secondary to lymphoma:

    • * >=1,000/mcL
    • * >=8 g/dL
    • >=75,000/mcL
    • (INR) \<=1.5 X institutional (ULN) for patients not receiving therapeutic anticoagulation
    • Partial thromboplastin time (PTT)/Activated partial thromboplastin time (aPTT) \<=1.5 X institutional ULN normal except if, in the opinion of the investigator, the aPTT is elevated because of a positive Lupus Anticoagulant, or a significant bleeding risk has been ruled out in the absence of a positive Lupus Anticoagulant
    • total \<=1.5 X institutional ULN (or \<=3 X institutional ULN for patients with documented Gilberts syndrome identified by an isolated unconjugated hyperbilirubinemia in the absence of other signs of liver dysfunction and/or uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) mutational testing)
    • (AST)Serum glutamic-oxaloacetic transaminase (SGOT)/Alanine aminotransferase (ALT)Serum glutamic-pyruvic transaminase (SGPT) \<=3 X institutional ULN
    • Serum creatinine \<=2.0 mg/dL OR
    • >=30 mL/min/1.73 m\^2 for patients with creatinine levels above 2 mg/dL

NOTE: Creatinine clearance (Cr Cl) will be calculated with the use of the 24-hour creatinine clearance or estimated (eGRF) in the clinical lab

  • Red blood cell (RBC) transfusions and use of granulocyte colony-stimulating factor (G-CSF) will be allowed in order to meet eligibility parameters.

    • Immune-modulating drugs (IMiDs) including Revlimid(R) are known to be teratogenic and potential embryo-fetal harm can be seen with use of polatuzumab, venetoclax and ibrutinib. The effects of obinutuzumab on the developing human fetus is unknown. For these reasons, individuals of and individuals able to father a child must agree to use adequate as described below.

      • For individuals of childbearing potential:

        • Agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of \< 1% per year as outlined below.
        • Agreement to refrain from donating eggs during timelines specified below.
        • Individuals of childbearing potential (ICBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days and again within 24 hours prior to prescribing Revlimid(R) for Cycle 1 (prescriptions must be filled within 7 days as required by Revlimid Risk Evaluation and Mitigation Strategy (REMSTM) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking Revlimid(R) ICBP must also agree to ongoing pregnancy testing.
        • An individual is considered to be of childbearing potential if that person is post-menarcheal, has not reached a state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).
        • Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
        • The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.
      • For individuals able to father a child:

        • Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:
        • With partners of childbearing potential, individuals able to father a child must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \< 1% per year as noted below. Individuals must refrain from donating sperm during this same period.
        • With pregnant partners, individuals must remain abstinent or use a condom as noted below to avoid exposing the embryo.
        • The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.
    • Contraception Requirements

      • Time frame/Study Drug (Pre-Treatment/During Treatment) - Individuals of childbearing potential (Time frame prior to/during dosing) / Individuals able to father a child (Time frame prior to/during dosing):

        ---All drugs; Begins 28 days prior to treatment; Begins on day 1

      • Time frame/Study Drug (Post-Treatment) - Individuals of childbearing potential (Time frame after the last dose) / Individuals able to father a child (Time frame after the last dose):

        • Venetoclax - 90 days / 90 days
        • Ibrutinib - 3 months / 3 months
        • Obinutuzumab - 18 months / 6 months
        • Revlimid(R) - 28 days / 28 days
        • Polatuzumab - 3 months / 5 months
    • All study participants must be registered into the mandatory Revlimid REMSTM program and be willing and able to comply with the requirements of Revlimid REMSTM. NOTE: Individuals of must adhere to the scheduled pregnancy testing as required in the Revlimid REMSTM program.
    • Ability of subject to understand and the willingness to sign a written document.

Exclusion criteria

EXCLUSION CRITERIA:

  • The following restrictions apply to current or prior anti-cancer treatment, prior to the first dose of study drug:

    • Patients who are actively receiving any other agents.
    • Any chemotherapy or anti-cancer antibodies within 2 weeks. NOTE: Short courses of or palliative radiation therapy (XRT) prior to enrollment are permitted within the 2- week .
    • Radio- or toxin-immunoconjugates within 10 weeks.
    • Previous treatment with more than one of the study agents (i.e., polatuzumab, venetoclax, ibrutinib, or Revlimid(R)), excluding prior prednisone or anti-CD20 antibody treatment.
    • Prior allogeneic stem cell (or other organ) transplant within 6 months or any evidence of active or requirement for within 28 days.
    • Not recovered (i.e., \<= Grade 1 or baseline) from adverse events due to previously administered anti-cancer treatment, surgery, or procedure. NOTE: Exceptions to this include events not considered to place the subject at unacceptable risk of participation in the opinion of the PI (e.g., alopecia).
  • Patients requiring the use of warfarin are excluded because of potential drug-drug interactions that may potentially increase the exposure of warfarin.
  • Patients requiring the following agents to the first dose of venetoclax or ibrutinib are excluded, as noted:

    • Strong cytochrome P450, family 3, subfamily A () inhibitors within 7 days
    • Strong CYP3A inducers within 7 days

NOTE: Moderate CYP3A inhibitors and inducers should be used with caution and an alternative medication used, whenever possible.

  • Uncontrolled intercurrent illness including, but not limited to the following that may limit interpretation of results or that could increase risk to the patient at the discretion of the investigator:

    • Symptomatic congestive heart failure, unstable angina pectoris, or uncontrolled cardiac arrhythmia
    • Uncontrolled and/or symptomatic thyroid disease
    • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with intravenous (IV) antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 2 weeks prior to Cycle 1, Day 1;
    • history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis; as well as active infection with virus (HBV) or virus (HCV):

      • Patients who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation
      • Patients with occult or prior HBV infection (defined as positive hepatitis B surface antigen (HBsAg) or positive hepatitis B core antibody (HBcAb) and with negative HBsAg) may be included if HBV deoxyribonucleic acid (DNA) is undetectable (i.e., none detected in copies/mL or IU/mL). These patients must be willing to undergo HBV DNA testing during treatment and in surveillance for at least 12 months after completion of study therapy.
    • Malabsorption syndrome or other condition that precludes enteral route of administration
    • Psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant individuals, or individuals who intend to become pregnant during the study, are excluded from this study because Revlimid(R) has known teratogenic effects and polatuzumab, venetoclax, ibrutinib and obinutuzumab are agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, nursing should be discontinued if the individual is treated on study.
  • (HIV)-positive patients are ineligible because of the potential for pharmacokinetic interactions with venetoclax, ibrutinib and Revlimid(R) and combination antiretroviral therapy. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
  • Evidence of active tumor lysis syndrome based on laboratory assessment
  • History of recent major surgery within 6 weeks prior to the start of Cycle 1, Day 1 other than for diagnosis
  • History of other active that could affect compliance with the protocol or interpretation of results

    • Patients with a history of curatively treated basal or squamous cell carcinoma or stage 1 melanoma of the skin as well as any in situ carcinoma are eligible.
    • Patients with a malignancy that has been treated with curative intent will also be eligible. Individuals in documented remission who are not receiving active treatment prior to enrollment may be included at the discretion of the investigator.
  • Known allergy to both xanthine oxidase inhibitors and rasburicase; or known to any of the study drugs
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Arm 1: Dose Escalation with Venetoclax,Ibrutinib,Prednisone,Obinutuzumab,Lenalidomide,Polatuzumab

    Venetoclax by mouth (PO) at escalating doses (2 dose levels) on days 2-14, ibrutinib (PO) 560mg on days 1-14, prednisone (PO) 100mg on days 1-7, obinutuzumab 1000mg intravenous (IV) on days 1 and 2, lenalidomide (PO) 15mg on days 1-14, and polatuzumab (IV) at escalating doses (2 dose levels) on day 2 of each 21-day cycle (maximum 6 cycles) to determine maximum tolerated dose (MTD) of polatuzumab and venetoclax.

    Biological: Obinutuzumab · Drug: Prednisone · Drug: Revlimid · Biological: Polatuzumab · Drug: Ibrutinib · Drug: Venetoclax · Diagnostic Test: EKG · Procedure: Bone marrow aspiration · Procedure: Bone marrow biopsy · Diagnostic Test: CT · Diagnostic Test: MRI · Diagnostic Test: PET · Procedure: Tumor tissue/Biopsy · Drug: Acetaminophen · Drug: Diphenhydramine

  • Experimental
    Arm 2: Dose Expansion with Venetoclax,Ibrutinib,Prednisone,Obinutuzumab,Lenalidomide,Polatuzumab

    Venetoclax by mouth (PO) at the maximum tolerated dose (MTD) days 2-14, ibrutinib (PO) 560mg on days 1-14, prednisone (PO) 100mg on days 1-7, obinutuzumab 1000mg intravenous (IV) on days 1 and 2, lenalidomide (PO) 15mg on days 1-14, and polatuzumab (IV) at the MTD of each 21-day cycle (maximum 6 cycles)

    Biological: Obinutuzumab · Drug: Prednisone · Drug: Revlimid · Drug: Ibrutinib · Diagnostic Test: EKG · Procedure: Bone marrow aspiration · Procedure: Bone marrow biopsy · Diagnostic Test: CT · Diagnostic Test: MRI · Diagnostic Test: PET · Procedure: Tumor tissue/Biopsy · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Venetoclax · Drug: Polatuzumab

Interventions

  • BiologicalObinutuzumab

    Administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity.

    Also known as: Gazyva

  • Administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity.

    Also known as: Deltasone, Sterapred

  • DrugLenalidomideStudies of LenalidomideLenalidomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered orally, days 1-14, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity.

    Also known as: Lenalidomide

  • BiologicalPolatuzumab

    Administered intravenously, on day 2, at varying doses of 1.4-1.8 mg/kg (based upon assigned dose level) in Arm 1 every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity. Also given at the MTD in Arm 2 (Dose Expansion).

    Also known as: Polivy

  • Administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity.

    Also known as: Imbruvica

  • Administered orally, days 2-14, at varying doses of 600 mg - 800 mg (based upon assigned dose level) in Arm 1 every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity. Also given at the maximum tolerated dose (MTD) in Arm 2 (Dose Expansion).

    Also known as: Venclexta

  • Diagnostic testEKG

    Screening

    Also known as: Electrocardiogram

  • ProcedureBone marrow aspiration

    Baseline, end of treatment/disease progression, and in follow-up as clinically indicated.

    Also known as: BM aspiration

  • ProcedureBone marrow biopsy

    Baseline, end of treatment/disease progression, and in follow-up as clinically indicated.

    Also known as: BM Bx

  • Diagnostic testCT

    Screening, Cycle 1/Day1, pre-cycle 3 \& 5, disease progression/end of treatment, and post treatment follow-up.

    Also known as: Computed tomography

  • Diagnostic testMRI

    MRI (optional) is an allowed alternative to CT per protocol. Screening, Cycle 1/Day1 (pre-cycle 3 \& 5), disease progression/end of treatment, and post treatment follow-up.

    Also known as: Magnetic resonance imaging

  • Diagnostic testPET

    Baseline, end of treatment, and at progressive disease.

    Also known as: Positron emission tomography

  • ProcedureTumor tissue/Biopsy

    Baseline, disease progression/end of treatment and disease progression post treatment follow-up.

    Also known as: Tumor tissue/Bx

  • Premedication 30-60 minutes before Obinutuzumab.

    Also known as: Tylenol, Paracetamol, Panadol, Mapap, APAP

  • Premedication 30-60 minutes before Obinutuzumab.

    Also known as: Diphenhydramine HCL, Diphenhydramine hydrochloride, Benadryl

  • Administered orally, days 2-14, at the maximum tolerated dose (MTD) every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity.

    Also known as: Venclexta

  • Administered intravenously, on day 2, at the maximum tolerated dose (MTD) every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity.

    Also known as: Polivy

07

What researchers measure

Primary outcomes

  1. Dose Escalation: Number of Grade 3, 4 and/or 5 Dose-limiting (DLT) Adverse Events at Each Dose Level With Type

    Number, type and grade of adverse events at each dose level was assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. A DLT is a grade 3 or higher adverse event at least possibly related to the study agent that occurs within the first 21 days of Cycle 1 of treatment.

    Time frame: 21 days

  2. Maximum Tolerated Dose (MTD) of Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

    MTD is defined as the dose level at which no more than 1 of up to 6 participants experience a dose-limiting toxicity, or the dose level below that at which at least 2 (of ≤6) participants have a DLT. A DLT is a grade 3 or higher adverse event at least possibly related to the study agent that occurs within the first 21 days of Cycle 1 of treatment. Such as Grade 3 nausea with maximum medical supportive care and persisting ≤7 days; Grade 3 vomiting or diarrhea f the participant does not require total parenteral nutrition (TPN), tube feeding, or hospitalization, and the toxicity improves to \< grade 3 within ≤3 days; Grade 3 fatigue persisting ≤7 days; Grade 3 fever or infection; Grade 3 infusion related reaction; Grade 3 febrile neutropenia; Grade 3 or Grade 4 neutropenia, Grade 3 thrombocytopenia not associated with grade 2 or greater bleeding; Grade 3 anemia persisting ≤7 days; and treatment delay of Cycle 2 for ≤7 days for hematologic toxicity.

    Time frame: 21 Days (Cycle 1)

  3. Maximum Tolerated Dose (MTD) of Venetoclax in Relapsed/Refractory B-cell Lymphoma

    MTD is defined as the dose level at which no more than 1 of up to 6 participants experience a dose-limiting toxicity, or the dose level below that at which at least 2 (of ≤6) participants have a DLT. A DLT is a grade 3 or higher adverse event at least possibly related to the study agent that occurs within the first 21 days of Cycle 1 of treatment. Such as Grade 3 nausea with maximum medical supportive care and persisting ≤7 days; Grade 3 vomiting or diarrhea f the participant does not require total parenteral nutrition (TPN), tube feeding, or hospitalization, and the toxicity improves to \< grade 3 within ≤3 days; Grade 3 fatigue persisting ≤7 days; Grade 3 fever or infection; Grade 3 infusion related reaction; Grade 3 febrile neutropenia; Grade 3 or Grade 4 neutropenia, Grade 3 thrombocytopenia not associated with grade 2 or greater bleeding; Grade 3 anemia persisting ≤7 days; and treatment delay of Cycle 2 for ≤7 days for hematologic toxicity.

    Time frame: 21 Days (Cycle 1)

Secondary outcomes

  1. Overall Response Rate (ORR)

    Overall response rate was assessed by the Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Complete response is no extralymphatic sites of disease or new lesions, and target nodes/nodal masses must regress to ≤1.5 cm in longest diameter. of a lesion. Partial response is ≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions (SPD) of up to 6 target measurable nodes and extranodal sites. Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir and an increase in LDi or shortest axis perpendicular to the LDi (SDi) from nadir; 0.5 cm for lesions ≤2 cm and 1.0 cm for lesions \>2 cm. Also new or clear progression of pre-existing nonmeasured lesions. ORR was measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval.

    Time frame: Every 42 days for 3 assessments (e.g., every 2 cycles) and/or end of treatment, up to 18 weeks

  2. Duration of Response

    DOR is defined as the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented or death, assessed every 3-12 months, measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval. Response was assessed by the Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Complete response is no extralymphatic sites of disease or new lesions, and target nodes/nodal masses must regress to ≤1.5 cm in longest diameter. Partial response is ≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions (SPD) of up to 6 target measurable nodes and extranodal sites. Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir.

    Time frame: Time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented or death

  3. Progression-free Survival (PFS)

    PFS is defined as the time from date of study enrollment until time of disease relapse, disease progression, or death, whichever occurs first, assessed every 3-12 months measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval. Response was assessed by the Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Disease relapse is Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir.

    Time frame: Time from date of study enrollment until time of disease relapse, disease progression, or death, whichever occurs first

  4. Event-free Survival (EFS)

    EFS is defined as the time from the date of study enrollment until time of disease relapse, disease progression, alternative therapy for lymphoma given (such as radiation), or death, whichever occurs first, assessed every 3-12 months. measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval. Response was assessed by the Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Diseae relapse is Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir.

    Time frame: Time from the date of study enrollment until time of disease relapse, disease progression, alternative therapy for lymphoma given (such as radiation), or death, whichever occurs first

  5. Overall Survival (OS)

    OS is defined as the time from the date of study enrollment until death from any cause, assessed every 3-12 months measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval.

    Time frame: Time from the date of study enrollment until death from any cause

  6. Complete Response Rate in Non-Germinal Center B-cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) Treated at the Maximum Tolerated Dose (MTD)

    Complete response rate is based on Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Complete response is no extralymphatic sites of disease or new lesions, and target nodes/nodal masses must regress to ≤1.5 cm in longest diameter of a lesion. Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir and an increase in LDi or shortest axis perpendicular to the LDi (SDi) from nadir; 0.5 cm for lesions ≤2 cm and 1.0 cm for lesions \>2 cm. Also new or clear progression of pre-existing nonmeasured lesions. Complete response is measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval.

    Time frame: Every 42 days for 3 assessments (e.g., every 2 cycles) and/or end of treatment, up to 18 weeks

Other outcomes

  1. Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

    Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

    Time frame: Adverse Events were monitored/assessed from the date of first dose of any study drug, through 30 days after the last dose of any study drug, an average of 5.2 months

08

Results

Posted Nov 12, 2026

Participant flow

Dose Escalation
Participant flow — Dose Escalation
MilestoneParticipant Consented, Enrolled But Not TreatedIndolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3
Started036600
Completed036600
Not completed000000
Dose Expansion
Participant flow — Dose Expansion
MilestoneParticipant Consented, Enrolled But Not TreatedIndolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3
Started1000825
Completed0000825
Not completed100000
Withdrew: Screen failure100000

Outcome measures

PrimaryDose Escalation: Number of Grade 3, 4 and/or 5 Dose-limiting (DLT) Adverse Events at Each Dose Level With Type

Number, type and grade of adverse events at each dose level was assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. A DLT is a grade 3 or higher adverse event at least possibly related to the study agent that occurs within the first 21 days of Cycle 1 of treatment.

Time frame:
21 days
Reported as:
Number · Adverse events
Dose Escalation: Number of Grade 3, 4 and/or 5 Dose-limiting (DLT) Adverse Events at Each Dose Level With Type
Adverse eventsIndolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3
Grade 4 Thrombocytopenia persisting for >7 days001
No Grade 3 and 5 Adverse Events That Met DLT Criteria000
PrimaryMaximum Tolerated Dose (MTD) of Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

MTD is defined as the dose level at which no more than 1 of up to 6 participants experience a dose-limiting toxicity, or the dose level below that at which at least 2 (of ≤6) participants have a DLT. A DLT is a grade 3 or higher adverse event at least possibly related to the study agent that occurs within the first 21 days of Cycle 1 of treatment. Such as Grade 3 nausea with maximum medical supportive care and persisting ≤7 days; Grade 3 vomiting or diarrhea f the participant does not require total parenteral nutrition (TPN), tube feeding, or hospitalization, and the toxicity improves to \< grade 3 within ≤3 days; Grade 3 fatigue persisting ≤7 days; Grade 3 fever or infection; Grade 3 infusion related reaction; Grade 3 febrile neutropenia; Grade 3 or Grade 4 neutropenia, Grade 3 thrombocytopenia not associated with grade 2 or greater bleeding; Grade 3 anemia persisting ≤7 days; and treatment delay of Cycle 2 for ≤7 days for hematologic toxicity.

Time frame:
21 Days (Cycle 1)
Reported as:
Number · mg/kg
Maximum Tolerated Dose (MTD) of Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
mg/kgDose Escalation: All Participants
Maximum Tolerated Dose (MTD) of Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma1.8
PrimaryMaximum Tolerated Dose (MTD) of Venetoclax in Relapsed/Refractory B-cell Lymphoma

MTD is defined as the dose level at which no more than 1 of up to 6 participants experience a dose-limiting toxicity, or the dose level below that at which at least 2 (of ≤6) participants have a DLT. A DLT is a grade 3 or higher adverse event at least possibly related to the study agent that occurs within the first 21 days of Cycle 1 of treatment. Such as Grade 3 nausea with maximum medical supportive care and persisting ≤7 days; Grade 3 vomiting or diarrhea f the participant does not require total parenteral nutrition (TPN), tube feeding, or hospitalization, and the toxicity improves to \< grade 3 within ≤3 days; Grade 3 fatigue persisting ≤7 days; Grade 3 fever or infection; Grade 3 infusion related reaction; Grade 3 febrile neutropenia; Grade 3 or Grade 4 neutropenia, Grade 3 thrombocytopenia not associated with grade 2 or greater bleeding; Grade 3 anemia persisting ≤7 days; and treatment delay of Cycle 2 for ≤7 days for hematologic toxicity.

Time frame:
21 Days (Cycle 1)
Reported as:
Number · mg
Maximum Tolerated Dose (MTD) of Venetoclax in Relapsed/Refractory B-cell Lymphoma
mgDose Escalation: All Participants
Maximum Tolerated Dose (MTD) of Venetoclax in Relapsed/Refractory B-cell Lymphoma800
SecondaryOverall Response Rate (ORR)

Overall response rate was assessed by the Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Complete response is no extralymphatic sites of disease or new lesions, and target nodes/nodal masses must regress to ≤1.5 cm in longest diameter. of a lesion. Partial response is ≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions (SPD) of up to 6 target measurable nodes and extranodal sites. Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir and an increase in LDi or shortest axis perpendicular to the LDi (SDi) from nadir; 0.5 cm for lesions ≤2 cm and 1.0 cm for lesions \>2 cm. Also new or clear progression of pre-existing nonmeasured lesions. ORR was measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval.

Time frame:
Every 42 days for 3 assessments (e.g., every 2 cycles) and/or end of treatment, up to 18 weeks
Reported as:
Number · proportion of participants
Overall Response Rate (ORR)
proportion of participantsIndolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3Total
Complete Response (CR)0.67 (0.12 to 0.98)0.5 (0.19 to 0.81)0.5 (0.19 to 0.81)0.5 (0.22 to 0.79)0.68 (0.48 to 0.83)0.60 (0.46 to 0.73)
Partial Response (PR)0.00 (0.00 to 0.56)0.33 (0.06 to 0.70)0.00 (0.00 to 0.39)0.38 (0.14 to 0.69)0.2 (0.09 to 0.39)0.21 (0.12 to 0.34)
Stable Disease (SD)0.33 (0.02 to 0.88)0.17 (0.01 to 0.56)0.5 (0.19 to 0.81)0.00 (0.00 to 0.32)0.04 (0.00 to 0.20)0.13 (0.06 to 0.25)
Progressive Disease (PD)0.00 (0.00 to 0.56)0.00 (0.00 to 0.39)0.00 (0.00 to 0.47)0.13 (0.01 to 0.47)0.08 (0.01 to 0.25)0.06 (0.02 to 0.17)
SecondaryDuration of Response

DOR is defined as the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented or death, assessed every 3-12 months, measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval. Response was assessed by the Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Complete response is no extralymphatic sites of disease or new lesions, and target nodes/nodal masses must regress to ≤1.5 cm in longest diameter. Partial response is ≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions (SPD) of up to 6 target measurable nodes and extranodal sites. Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir.

Time frame:
Time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented or death

Results for this outcome have not been posted.

SecondaryProgression-free Survival (PFS)

PFS is defined as the time from date of study enrollment until time of disease relapse, disease progression, or death, whichever occurs first, assessed every 3-12 months measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval. Response was assessed by the Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Disease relapse is Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir.

Time frame:
Time from date of study enrollment until time of disease relapse, disease progression, or death, whichever occurs first

Results for this outcome have not been posted.

SecondaryEvent-free Survival (EFS)

EFS is defined as the time from the date of study enrollment until time of disease relapse, disease progression, alternative therapy for lymphoma given (such as radiation), or death, whichever occurs first, assessed every 3-12 months. measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval. Response was assessed by the Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Diseae relapse is Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir.

Time frame:
Time from the date of study enrollment until time of disease relapse, disease progression, alternative therapy for lymphoma given (such as radiation), or death, whichever occurs first

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

OS is defined as the time from the date of study enrollment until death from any cause, assessed every 3-12 months measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval.

Time frame:
Time from the date of study enrollment until death from any cause

Results for this outcome have not been posted.

SecondaryComplete Response Rate in Non-Germinal Center B-cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) Treated at the Maximum Tolerated Dose (MTD)

Complete response rate is based on Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Complete response is no extralymphatic sites of disease or new lesions, and target nodes/nodal masses must regress to ≤1.5 cm in longest diameter of a lesion. Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir and an increase in LDi or shortest axis perpendicular to the LDi (SDi) from nadir; 0.5 cm for lesions ≤2 cm and 1.0 cm for lesions \>2 cm. Also new or clear progression of pre-existing nonmeasured lesions. Complete response is measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval.

Time frame:
Every 42 days for 3 assessments (e.g., every 2 cycles) and/or end of treatment, up to 18 weeks
Reported as:
Number · proportion of participants
Complete Response Rate in Non-Germinal Center B-cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) Treated at the Maximum Tolerated Dose (MTD)
proportion of participantsIndolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DLTotal
Complete Response Rate in Non-Germinal Center B-cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) Treated at the Maximum Tolerated Dose (MTD)0.75 (0.30 to 0.99)0.67 (0.12 to 0.98)0.68 (0.48 to 0.83)0.69 (0.51 to 0.82)
Other pre-specifiedNumber of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Time frame:
Adverse Events were monitored/assessed from the date of first dose of any study drug, through 30 days after the last dose of any study drug, an average of 5.2 months
Reported as:
Count of participants · Participants
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
ParticipantsIndolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)366825

Adverse events

Collected over All-Cause Mortality was monitored/assessed, up to 60.0 months. Adverse Events were monitored/assessed from the date of first dose of any study drug, through 30 days after the last dose of any study drug, up to 5.2 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 12/3 (66.7%)1/3 (33.3%)3/3 (100%)
Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 21/6 (16.7%)1/6 (16.7%)6/6 (100%)
Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 34/6 (66.7%)3/6 (50%)6/6 (100%)
Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 35/8 (62.5%)4/8 (50%)8/8 (100%)
Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 39/25 (36%)12/25 (48%)25/25 (100%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventIndolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3
HypokalemiaMetabolism and nutrition disorders1/30/60/60/81/25
Febrile neutropeniaBlood and lymphatic system disorders0/30/60/62/81/25
FeverGeneral disorders and administration site conditions0/31/61/61/82/25
Hepatobiliary disorders - Other, specify: Drug induced liver injuryHepatobiliary disorders0/31/60/60/80/25
COVID-19 InfectionInfections and infestations0/30/61/60/80/25
Skin infectionInfections and infestations0/30/61/60/80/25
Alanine aminotransferase increasedInvestigations0/31/60/60/80/25
Aspartate aminotransferase increasedInvestigations0/31/60/60/80/25
Blood bilirubin increasedInvestigations0/31/60/60/80/25
Thromboembolic eventVascular disorders0/30/61/60/80/25
Most frequent other events
Showing 10 of 88
Most frequent other events
EventIndolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3
AnemiaBlood and lymphatic system disorders2/35/66/67/824/25
Alanine aminotransferase increasedInvestigations3/34/64/63/816/25
Alkaline phosphatase increasedInvestigations3/34/61/63/815/25
Platelet count decreasedInvestigations3/36/66/67/824/25
HypokalemiaMetabolism and nutrition disorders3/36/66/67/825/25
HypomagnesemiaMetabolism and nutrition disorders3/31/62/64/814/25
DiarrheaGastrointestinal disorders2/35/65/66/821/25
NauseaGastrointestinal disorders2/31/65/64/85/25
Blood bilirubin increasedInvestigations1/32/62/63/820/25
Neutrophil count decreasedInvestigations1/32/64/66/819/25

Baseline characteristics

All participants consented and enrolled who had data collected are reported in the table.

Age, Categorical
Age, Categorical(Participants)Participant Consented, Enrolled But Not TreatedIndolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3Total
<=18 years0000000
Between 18 and 65 years135561535
>=65 years001121014
Age, Continuous
Age, Continuous(years)Participant Consented, Enrolled But Not TreatedIndolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3Total
Mean5359 ± 754.17 ± 14.851.33 ± 12.5354.63 ± 15.8158.64 ± 14.4756.45 ± 13.79
Sex: Female, Male
Sex: Female, Male(Participants)Participant Consented, Enrolled But Not TreatedIndolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3Total
Female02131714
Male115371835
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Participant Consented, Enrolled But Not TreatedIndolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3Total
American Indian or Alaska Native0010001
Asian0101013
Native Hawaiian or Other Pacific Islander0001001
Black or African American00121711
White124271632
More than one race0000000
Unknown or Not Reported0000011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Participant Consented, Enrolled But Not TreatedIndolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3Total
Hispanic or Latino0020002
Not Hispanic or Latino134682547
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(participants)Participant Consented, Enrolled But Not TreatedIndolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3Total
United States136682549
Disease Histology
Disease Histology(Participants)Participant Consented, Enrolled But Not TreatedIndolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3Total
Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma (GCB DLBCL)1010002
High-Grade B-Cell Lymphoma, Double-Hit, with B-cell Lymphoma 2 rearrangement (HGBCL-DH-BCL2)02225011
High-Grade B-Cell Lymphoma, Double-Hit, with B-cell Lymphoma 6 rearrangement (HGBCL-DH-BCL6)0000112
Non-Germinal Center B-cell-like Diffuse Large B-Cell Lymphoma (Non-GCB DLBCL)013421929
T-cell/Histiocyte Rich Large B Cell Lymphoma (THRLBCL)0000055
09

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request. In addition, all large-scale genomic sequencing data will be shared with subscribers to the database of Genotypes and Phenotypes (dbGaP). All collected IPD will be shared with collaborators under the terms of collaborative agreements.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Clinical data will be available during the study and indefinitely. Genomic data will be available once genomic data are uploaded per protocol Genomic Data Sharing (GDS) plan for as long as database is active.

Access criteria: Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI). Genomic data will be made available via the database of Genotypes and Phenotypes (dbGaP) through requests to the data custodians.

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in May 2026, 57 months.

Results were first posted in Nov 2026, 6 months after primary completion.

Of 123 non-industry phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 80. This study's 57 months is close to that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2031 → May 2031, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2021
First posted
Feb 5, 2021
StartActual
Jul 9, 2021
Primary completionActual
May 7, 2026
CompletionEst.
May 7, 2031was Jun 2031
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 12, 2026
Study completion
Jun 18, 2031→May 7, 2031
Nov 12, 2026
Enrollment
34→49
Nov 12, 2026
Eligibility
17 inclusion criteria edited; 7 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedPatients must have histologically or cytologically confirmed B-cell lymphoma confirmed by the Laboratory of Pathology, National Cancer Institute (NCI), as follows:
  • EditedAggressive B-cell lymphoma: includes diffuse large B-cell lymphoma (DLBCL) and subtypes, transformed lymphoma, Burkitt lymphoma, as well as high-grade B-cell lymphoma with MYC and/or B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangement(s).
  • EditedMantle cell lymphoma (MCL) is excluded given increased risk of tumor lysis syndrome (TLS) with venetoclax compared to other non-Hodgkin lymphomas and need for venetoclax ramp-up, dose-escalation.
  • EditedChronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) is excluded given alternative dosing of Food and Drug Administration (FDA)-approved venetoclax for relapsed CLL/SLL and increased risk of TLS with CLL/SLL compared to other non-Hodgkin lymphomas.
  • Edited-Non-germinal center B-cell-like (Non-GCB) DLBCL: includes DLBCL not otherwise specified (NOS) and subtypes, transformed lymphoma, T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL), as well as high-grade B-cell lymphoma with MYC and/or BCL6 rearrangement(s).
  • EditedNOTE: Patients with known active central nervous system (CNS) lymphoma are not eligible.
  • EditedIndolent B-cell lymphoma: relapsed after and/or refractory to at least 1 prior anti- cluster of differentiation 20 (CD20) antibody-containing regimen.
  • EditedPatients must have evaluable disease by clinical exam (i.e., palpable lymphadenopathy, measurable skin lesions, etc.), laboratory assessment (i.e., lymphoma involvement of bone marrow or peripheral blood by morphology, cytology or flow cytometry), and/or imaging (measurable lymph nodes or masses on computed tomography (CT) or magnetic resonance imaging (MRI) and/or evaluable fluorodeoxyglucose (FDG)-avid lesions on positron emission tomography (PET).
  • EditedEastern Cooperative Oncology (ECOG) performance status <=2.
  • EditedInternational Normalized Ratio (INR) <=1.5 X institutional upper limit of normal (ULN) for patients not receiving therapeutic anticoagulation
  • EditedPartial thromboplastin time (PTT)/Activated partial thromboplastin time (aPTT) <=1.5 X institutional ULN normal except if, in the opinion of the investigator, the aPTT is elevated because of a positive Lupus Anticoagulant, or a significant bleeding risk has been ruled out in the absence of a positive Lupus Anticoagulant
  • Editedtotal bilirubin <=1.5 X institutional ULN (or <=3 X institutional ULN for patients with documented Gilberts syndrome identified by an isolated unconjugated hyperbilirubinemia in the absence of other signs of liver dysfunction and/or uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) mutational testing)
  • EditedAspartate aminotransferase (AST)Serum glutamic-oxaloacetic transaminase (SGOT)/Alanine aminotransferase (ALT)Serum glutamic-pyruvic transaminase (SGPT) <=3 X institutional ULN
  • EditedCreatinine clearance >=30 mL/min/1.73 m2m\^2 for patients with creatinine levels above 2 mg/dL
  • EditedNOTE: Creatinine clearance (Cr Cl) will be calculated with the use of the 24-hour creatinine clearance or estimated glomerular filtration rate (eGRF) in the clinical lab
  • EditedRed blood cell (RBC) transfusions and use of granulocyte colony-stimulating factor (G-CSF) will be allowed in order to meet eligibility parameters.
  • EditedIndividuals of childbearing potential (ICBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days and again within 24 hours prior to prescribing Revlimid(R) for Cycle 1 (prescriptions must be filled within 7 days as required by Revlimid Risk Evaluation and Mitigation Strategy (REMSTM) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking Revlimid(R) ICBP must also agree to ongoing pregnancy testing.
Exclusion criteria
  • EditedAny chemotherapy or anti-cancer antibodies within 2 weeks. NOTE: Short courses of corticosteroids or palliative radiation therapy (XRT) prior to enrollment are permitted within the 2- week washout period.
  • EditedStrong cytochrome P450, family 3, subfamily A (CYP3A) inhibitors within 7 days
  • EditedKnown active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with intravenous (IV) antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 2 weeks prior to Cycle 1, Day 1;
  • EditedClinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis; as well as active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV):
  • EditedPatients with occult or prior HBV infection (defined as positive hepatitis B surface antigen (HBsAg) or positive hepatitis B core antibody (HBcAb) and with negative HBsAg) may be included if HBV deoxyribonucleic acid (DNA) is undetectable (i.e., none detected in copies/mL or IU/mL). These patients must be willing to undergo HBV DNA testing during treatment and in surveillance for at least 12 months after completion of study therapy.
  • EditedHuman immunodeficiency virus (HIV)-positive patients are ineligible because of the potential for pharmacokinetic interactions with venetoclax, ibrutinib and Revlimid(R) and combination antiretroviral therapy. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
  • EditedKnown allergy to both xanthine oxidase inhibitors and rasburicase; or, known hypersensitivity to any of the study drugs
Nov 12, 2026
Interventions
Added Drug: Venetoclax·Diagnostic test: EKG·Procedure: Bone marrow aspiration·Procedure: Bone marrow biopsy·Diagnostic test: CT·and 6 more
All 11

Drug: Venetoclax · Diagnostic test: EKG · Procedure: Bone marrow aspiration · Procedure: Bone marrow biopsy · Diagnostic test: CT · Diagnostic test: MRI · Diagnostic test: PET · Procedure: Tumor tissue/Biopsy · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Polatuzumab

; removed Drug: venetoclax. Arms added: Arm 1: Dose Escalation with Venetoclax,Ibrutinib,Prednisone,Obinutuzumab,Lenalidomide,Polatuzumab·Arm 2: Dose Expansion with Venetoclax,Ibrutinib,Prednisone,Obinutuzumab,Lenalidomide,Polatuzumab; arms removed: Arm 1: Dose Escalation·Arm 2: Dose Expansion
Nov 12, 2026
Primary outcomes
3 added, 2 removed
What changed in the outcomes
  • AddedDose Escalation: Number of Grade 3, 4 and/or 5 Dose-limiting (DLT) Adverse Events at Each Dose Level With TypeTime frame: 21 days
  • AddedMaximum Tolerated Dose (MTD) of Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaTime frame: 21 Days (Cycle 1)
  • AddedMaximum Tolerated Dose (MTD) of Venetoclax in Relapsed/Refractory B-cell LymphomaTime frame: 21 Days (Cycle 1)
  • RemovedNumber and grade of adverse eventsTime frame: 21 days
  • RemovedComplete response (CR) rateTime frame: every 42 days for 3 assessments (e.g., every 2 cycles) and/or end of treatment
Nov 12, 2026
Secondary outcomes
5 edited, 1 time frame changed, 1 added, 1 description edited
What changed in the outcomes
  • EditedDuration of Response (DOR)Time frame: For ORR-time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented or death, assessed every 3-6months, For CR-time measurement criteria are met for CR → Time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented or death
  • EditedProgression-free survivalSurvival (PFS)Time frame: time from date of study enrollment until time of disease relapse, disease progression, or death, whichever occurs first, assessed every 3-6 months → Time from date of study enrollment until time of disease relapse, disease progression, or death, whichever occurs first
  • EditedEvent-free survivalSurvival (EFS)Time frame: time from the date of study enrollment until time of disease relapse, disease progression, alternative therapy for lymphoma given (such as radiation), or death, whichever occurs first, assessed every 3-6 months → Time from the date of study enrollment until time of disease relapse, disease progression, alternative therapy for lymphoma given (such as radiation), or death, whichever occurs first
  • EditedOverall survivalSurvival (OS)Time frame: time from the date of study enrollment until death from any cause, assessed every 3-6 months → Time from the date of study enrollment until death from any cause
  • ChangedBefore Complete response (CR) rateNow Complete Response Rate in Non-Germinal Center B-cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) Treated at the Maximum Tolerated Dose (MTD)Time frame: time measurement criteria are met for CR until the first date that progressive disease is objectively documented or death, assessed every 3-6months → Every 42 days for 3 assessments (e.g., every 2 cycles) and/or end of treatment, up to 18 weeks
  • Time frameOverall Response Rate (ORR)time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented or death, assessed every 3-6months → Every 42 days for 3 assessments (e.g., every 2 cycles) and/or end of treatment, up to 18 weeks
  • DescriptionOverall Response Rate (ORR): how it is measured was reworded
  • Addedother outcomeNumber of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)Time frame: Adverse Events were monitored/assessed from the date of first dose of any study drug, through 30 days after the last dose of any study drug, an average of 5.2 months
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Results posted
    Study completion Jun 18, 2031→May 7, 2031
    Enrollment 34→49
    Eligibility 17 inclusion criteria edited; 7 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatients must have histologically or cytologically confirmed B-cell lymphoma confirmed by the Laboratory of Pathology, National Cancer Institute (NCI), as follows:
    • EditedAggressive B-cell lymphoma: includes diffuse large B-cell lymphoma (DLBCL) and subtypes, transformed lymphoma, Burkitt lymphoma, as well as high-grade B-cell lymphoma with MYC and/or B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangement(s).
    • EditedMantle cell lymphoma (MCL) is excluded given increased risk of tumor lysis syndrome (TLS) with venetoclax compared to other non-Hodgkin lymphomas and need for venetoclax ramp-up, dose-escalation.
    • EditedChronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) is excluded given alternative dosing of Food and Drug Administration (FDA)-approved venetoclax for relapsed CLL/SLL and increased risk of TLS with CLL/SLL compared to other non-Hodgkin lymphomas.
    • Edited-Non-germinal center B-cell-like (Non-GCB) DLBCL: includes DLBCL not otherwise specified (NOS) and subtypes, transformed lymphoma, T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL), as well as high-grade B-cell lymphoma with MYC and/or BCL6 rearrangement(s).
    • EditedNOTE: Patients with known active central nervous system (CNS) lymphoma are not eligible.
    • EditedIndolent B-cell lymphoma: relapsed after and/or refractory to at least 1 prior anti- cluster of differentiation 20 (CD20) antibody-containing regimen.
    • EditedPatients must have evaluable disease by clinical exam (i.e., palpable lymphadenopathy, measurable skin lesions, etc.), laboratory assessment (i.e., lymphoma involvement of bone marrow or peripheral blood by morphology, cytology or flow cytometry), and/or imaging (measurable lymph nodes or masses on computed tomography (CT) or magnetic resonance imaging (MRI) and/or evaluable fluorodeoxyglucose (FDG)-avid lesions on positron emission tomography (PET).
    • EditedEastern Cooperative Oncology (ECOG) performance status <=2.
    • EditedInternational Normalized Ratio (INR) <=1.5 X institutional upper limit of normal (ULN) for patients not receiving therapeutic anticoagulation
    • EditedPartial thromboplastin time (PTT)/Activated partial thromboplastin time (aPTT) <=1.5 X institutional ULN normal except if, in the opinion of the investigator, the aPTT is elevated because of a positive Lupus Anticoagulant, or a significant bleeding risk has been ruled out in the absence of a positive Lupus Anticoagulant
    • Editedtotal bilirubin <=1.5 X institutional ULN (or <=3 X institutional ULN for patients with documented Gilberts syndrome identified by an isolated unconjugated hyperbilirubinemia in the absence of other signs of liver dysfunction and/or uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) mutational testing)
    • EditedAspartate aminotransferase (AST)Serum glutamic-oxaloacetic transaminase (SGOT)/Alanine aminotransferase (ALT)Serum glutamic-pyruvic transaminase (SGPT) <=3 X institutional ULN
    • EditedCreatinine clearance >=30 mL/min/1.73 m2m\^2 for patients with creatinine levels above 2 mg/dL
    • EditedNOTE: Creatinine clearance (Cr Cl) will be calculated with the use of the 24-hour creatinine clearance or estimated glomerular filtration rate (eGRF) in the clinical lab
    • EditedRed blood cell (RBC) transfusions and use of granulocyte colony-stimulating factor (G-CSF) will be allowed in order to meet eligibility parameters.
    • EditedIndividuals of childbearing potential (ICBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days and again within 24 hours prior to prescribing Revlimid(R) for Cycle 1 (prescriptions must be filled within 7 days as required by Revlimid Risk Evaluation and Mitigation Strategy (REMSTM) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking Revlimid(R) ICBP must also agree to ongoing pregnancy testing.
    Exclusion criteria
    • EditedAny chemotherapy or anti-cancer antibodies within 2 weeks. NOTE: Short courses of corticosteroids or palliative radiation therapy (XRT) prior to enrollment are permitted within the 2- week washout period.
    • EditedStrong cytochrome P450, family 3, subfamily A (CYP3A) inhibitors within 7 days
    • EditedKnown active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with intravenous (IV) antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 2 weeks prior to Cycle 1, Day 1;
    • EditedClinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis; as well as active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV):
    • EditedPatients with occult or prior HBV infection (defined as positive hepatitis B surface antigen (HBsAg) or positive hepatitis B core antibody (HBcAb) and with negative HBsAg) may be included if HBV deoxyribonucleic acid (DNA) is undetectable (i.e., none detected in copies/mL or IU/mL). These patients must be willing to undergo HBV DNA testing during treatment and in surveillance for at least 12 months after completion of study therapy.
    • EditedHuman immunodeficiency virus (HIV)-positive patients are ineligible because of the potential for pharmacokinetic interactions with venetoclax, ibrutinib and Revlimid(R) and combination antiretroviral therapy. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
    • EditedKnown allergy to both xanthine oxidase inhibitors and rasburicase; or, known hypersensitivity to any of the study drugs
    Primary outcomes 3 added, 2 removed
    What changed in the outcomes
    • AddedDose Escalation: Number of Grade 3, 4 and/or 5 Dose-limiting (DLT) Adverse Events at Each Dose Level With TypeTime frame: 21 days
    • AddedMaximum Tolerated Dose (MTD) of Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaTime frame: 21 Days (Cycle 1)
    • AddedMaximum Tolerated Dose (MTD) of Venetoclax in Relapsed/Refractory B-cell LymphomaTime frame: 21 Days (Cycle 1)
    • RemovedNumber and grade of adverse eventsTime frame: 21 days
    • RemovedComplete response (CR) rateTime frame: every 42 days for 3 assessments (e.g., every 2 cycles) and/or end of treatment
    Secondary outcomes 5 edited, 1 time frame changed, 1 added, 1 description edited
    What changed in the outcomes
    • EditedDuration of Response (DOR)Time frame: For ORR-time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented or death, assessed every 3-6months, For CR-time measurement criteria are met for CR → Time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented or death
    • EditedProgression-free survivalSurvival (PFS)Time frame: time from date of study enrollment until time of disease relapse, disease progression, or death, whichever occurs first, assessed every 3-6 months → Time from date of study enrollment until time of disease relapse, disease progression, or death, whichever occurs first
    • EditedEvent-free survivalSurvival (EFS)Time frame: time from the date of study enrollment until time of disease relapse, disease progression, alternative therapy for lymphoma given (such as radiation), or death, whichever occurs first, assessed every 3-6 months → Time from the date of study enrollment until time of disease relapse, disease progression, alternative therapy for lymphoma given (such as radiation), or death, whichever occurs first
    • EditedOverall survivalSurvival (OS)Time frame: time from the date of study enrollment until death from any cause, assessed every 3-6 months → Time from the date of study enrollment until death from any cause
    • ChangedBefore Complete response (CR) rateNow Complete Response Rate in Non-Germinal Center B-cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) Treated at the Maximum Tolerated Dose (MTD)Time frame: time measurement criteria are met for CR until the first date that progressive disease is objectively documented or death, assessed every 3-6months → Every 42 days for 3 assessments (e.g., every 2 cycles) and/or end of treatment, up to 18 weeks
    • Time frameOverall Response Rate (ORR)time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented or death, assessed every 3-6months → Every 42 days for 3 assessments (e.g., every 2 cycles) and/or end of treatment, up to 18 weeks
    • DescriptionOverall Response Rate (ORR): how it is measured was reworded
    • Addedother outcomeNumber of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)Time frame: Adverse Events were monitored/assessed from the date of first dose of any study drug, through 30 days after the last dose of any study drug, an average of 5.2 months
    Interventions Added Drug: Venetoclax·Diagnostic test: EKG·Procedure: Bone marrow aspiration·Procedure: Bone marrow biopsy·Diagnostic test: CT·and 6 more
    All 11

    Drug: Venetoclax · Diagnostic test: EKG · Procedure: Bone marrow aspiration · Procedure: Bone marrow biopsy · Diagnostic test: CT · Diagnostic test: MRI · Diagnostic test: PET · Procedure: Tumor tissue/Biopsy · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Polatuzumab

    ; removed Drug: venetoclax. Arms added: Arm 1: Dose Escalation with Venetoclax,Ibrutinib,Prednisone,Obinutuzumab,Lenalidomide,Polatuzumab·Arm 2: Dose Expansion with Venetoclax,Ibrutinib,Prednisone,Obinutuzumab,Lenalidomide,Polatuzumab; arms removed: Arm 1: Dose Escalation·Arm 2: Dose Expansion
    + 6 other changes: verification date, responsible party, oversight details, description, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT04739813
Responsible party
Christopher Melani, MD (Principal Investigator, National Cancer Institute (NCI)) — Principal investigator
First posted
Feb 5, 2021
Start date
Jul 9, 2021
Primary completion
May 7, 2026
Completion
May 7, 2031 (estimated)
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Study contacts

Christopher J Melani, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Polatuzumab

Start the discussion